Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.300
+0.412 (46.40%)
At close: Dec 20, 2024, 4:00 PM
1.280
-0.020 (-1.54%)
After-hours: Dec 20, 2024, 7:59 PM EST

Prelude Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Selling, General & Admin
29.5628.8830.6526.9610.593.83
Upgrade
Research & Development
116.71103.3992.8986.7848.1824.28
Upgrade
Operating Expenses
146.26132.28123.54113.7458.7628.11
Upgrade
Operating Income
-143.26-132.28-123.54-113.74-58.76-28.11
Upgrade
Other Non Operating Income (Expenses)
11.7510.458.12.041.830.54
Upgrade
Pretax Income
-131.52-121.83-115.44-111.69-56.93-27.57
Upgrade
Net Income
-131.52-121.83-115.44-111.69-56.93-27.57
Upgrade
Net Income to Common
-131.52-121.83-115.44-111.69-56.93-27.57
Upgrade
Shares Outstanding (Basic)
74604746122
Upgrade
Shares Outstanding (Diluted)
74604746122
Upgrade
Shares Change (YoY)
35.27%27.41%2.87%269.03%647.86%18.93%
Upgrade
EPS (Basic)
-1.77-2.02-2.44-2.43-4.56-16.52
Upgrade
EPS (Diluted)
-1.77-2.02-2.44-2.43-4.56-16.52
Upgrade
Free Cash Flow
-107.56-110.58-86.75-85.85-46.8-26.45
Upgrade
Free Cash Flow Per Share
-1.45-1.83-1.83-1.86-3.75-15.85
Upgrade
EBITDA
-141.65-131.11-122.22-112.82-58.22-27.73
Upgrade
D&A For EBITDA
1.611.171.320.920.540.38
Upgrade
EBIT
-143.26-132.28-123.54-113.74-58.76-28.11
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.